Table Graph
   

anti-interleukin-6 - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.68, 1.22]< 135%18 studies (18/-)73.2 %some concernlow moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %NAnot evaluable crucial-
deaths 0.87 [0.75, 1.00]< 114%28 studies (28/-)97.8 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.08 [0.73, 1.59]< 156%5 studies (5/-)34.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.79 [0.60, 1.04]< 15%6 studies (6/-)95.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.26 [1.06, 1.49]> 139%7 studies (7/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %NAnot evaluable important-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.11 [0.95, 1.31]> 10%3 studies (3/-)90.2 %some concernnot evaluable moderateimportant-
death or ventilation 0.84 [0.74, 0.96]< 111%8 studies (8/-)99.6 %some concernnot evaluable moderateimportant-
hospital discharge 1.03 [0.88, 1.19]> 10%3 studies (3/-)63.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.82 [0.59, 1.13]< 10%6 studies (6/-)89.1 %some concernserious moderateimportant-
ICU admission 0.96 [0.54, 1.71]< 156%4 studies (4/-)55.4 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.98 [0.80, 1.20]< 10%9 studies (9/-)57.5 %some concernserious moderateimportant-
adverse events 1.37 [0.98, 1.93]< 157%7 studies (7/-)3.3 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons